Assess whether biosimilarity is analytically justified (02e55f)

Situation

Pharmacovigilance work in a 505(b)(2) program relying on literature plus a bridging study now turns on biosimilarity is analytically justified because a CRL citing manufacturing, not efficacy put complete-response-letter deficiency list in play. Pharmacovigilance work in a 505(b)(2) program relying on literature plus a bridging study now turns on biosimilarity is analytically justified because a CRL citing manufacturing, not efficacy put complete-response-letter deficiency list in play; clinical-development physician should say what complete-response-letter deficiency list proves for Pharma & Life Sciences.

Decision

Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• The population in complete-response-letter deficiency list is the one a CRL citing manufacturing, not efficacy named, so Proceed under protocol follows for this Pharmacovigilance file.
• The population in complete-response-letter deficiency list is adjacent only to a CRL citing manufacturing, not efficacy; Pause the pathway is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained a CRL citing manufacturing, not efficacy before complete-response-letter deficiency list arrived; no new Pharmacovigilance path.
• Provenance on complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Check whether complete-response-letter deficiency list supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy.
• For this Pharma & Life Sciences Pharmacovigilance file, read complete-response-letter deficiency list against a CRL citing manufacturing, not efficacy and write the one fact that would move biosimilarity is analytically justified for clinical-development physician.